Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
February 01, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike...
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
November 06, 2020 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor...